- Home
- RA vs KURA Comparison
RA vs KURA Comparison
Compare RA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RA | KURA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 709.5M | 841.6M |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RA | KURA |
|---|---|---|
| Price | $12.72 | $8.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 148.9K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $12.50 | $5.45 |
| 52 Week High | $13.59 | $12.49 |
Technical Indicators
Market Signals| Indicator | RA | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 44.04 |
| Support Level | $12.50 | $8.80 |
| Resistance Level | $13.00 | $10.16 |
| Average True Range (ATR) | 0.12 | 0.67 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 48.61 | 14.86 |
Price Performance
Historical ComparisonAbout RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.